Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion of Anrikefon in Hemodialysis Patients
NCT06238388Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hsk21542 in chronic kidney disease (CKD), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Cumulative recovery of unchanged drug at 168 hours, Cumulative recovery fraction of unchanged drug at 168 hours and 6 more. Started Oct 2023; status: completed.
02
Drugs
hsk21542
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06238388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238388.